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Abstract
The validation of tau radioligands could improve the diagnosis of frontotempo-
ral lobar degeneration and the assessment of disease-modifying therapies. Here,
we demonstrate that binding of the tau radioligand [18F]AV-1451 was signifi-
cantly abnormal in both magnitude and distribution in a patient with familial
frontotemporal dementia due to a MAPT 10 + 16C>T gene mutation, recapitu-
lating the pattern of neuropathology seen in her father. Given the genetic
diagnosis and the non-Alzheimer’s pathology, these findings suggest that
[18F]AV-1451 might be a useful biomarker in primary tauopathies. Largerscale
in vivo and post-mortem studies will be needed to assess the technique’s speci-
ficity.
Introduction
The pathogenic role of tau is well established in many
neurodegenerative diseases. Until recently it has only been
feasible to examine the morphology, intensity, and
distribution of tau pathology post-mortem. Several radio-
labeled compounds have been developed with evidence of
binding to intracellular aggregates of tau,1,2 allowing
potential visualization and quantification of tau pathology
using positron emission tomography (PET).
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
1
There is strong evidence in vivo and post-mortem that
[18F]AV-1451 binds paired helical filaments of tau in Alz-
heimer’s disease (AD).3,4 The distribution and magnitude
of in vivo tau binding correlates with AD staging,5 and
recapitulates the anatomical distribution of focal onset
forms including logopenic aphasia 6 and posterior cortical
atrophy.7 Binding to tau in primary, non-AD tauopathies
is less well established, with inconsistency between in vivo
PET findings and post-mortem analysis in progressive
supranuclear palsy.3,8,9
Genetically determined tauopathies provide an impor-
tant opportunity for validation of tau tracers. It has
recently been demonstrated that in advanced dementia
due to MAPT mutation, the regional [18F]AV-1451 bind-
ing in vivo correlates strongly with the density of tau
pathology post-mortem, and with glucose hypometabo-
lism,10 although differentiation between patients was not
established, in either distribution or magnitude of [18F]
AV-1451 PET. Here, we compare the magnitude and dis-
tribution of [18F]AV-1451 binding in healthy controls to
a patient with behavioral variant frontotemporal dementia
(bvFTD) resulting from a 10 + 16C>T mutation in the
microtubule-associated protein tau gene (MAPT).
Methods
Family history
Proband
The patient presented aged 51 with 3 years of gradual
change in behavior and difficulty managing daily affairs,
apathy, reduced empathy, obsessional behaviors, rigid rou-
tines, hyperphagia, and weight gain. Examination revealed
adynamic, empty speech with preserved grammar, reduced
verbal fluency, anomia, semantic deficits, and surface
dyslexia. Eye movements were normal. Praxis, cortical sen-
sation, and visuospatial function were intact. There were
no cerebellar or extrapyramidal features and no signs of
anterior horn cell disease. She scored 36/100 on the Adden-
brooke’s Cognitive Examination (revised), and 3/26 on the
frontotemporal dementia functional rating scale,11 indicat-
ing severe deficits. Magnetic resonance imaging revealed
asymmetric, predominantly left-sided, frontotemporal
atrophy. She and her father had a 10 + 16C>T mutation of
MAPT, with an H1H1 haplotype.
Father
The patient’s father presented at age of 59 years with
10 years of insidious personality change and inappropri-
ate behavior without insight. He was disinhibited, rest-
less, hyperphagic for sweet foods, with cognitive rigidity,
stereotyped behaviors, and later apathy. He had semantic
memory impairment, poor verbal fluency, anomia, and
surface dyslexia. Visuospatial function and orientation
were intact. There were no ocular or motor abnormali-
ties. His initial Addenbrooke’s Cognitive Examination
score was 77/100. MRI showed frontal and anterior tem-
poral lobe atrophy, more marked on the left. He died
aged 63.
Neuropathological examination (see Appendix for
detail) showed moderate cerebral atrophy, most promi-
nent in the frontal and temporal lobes, especially on the
left. There was mild neuronal loss and gliosis throughout
cortex, without neuritic plaques. Ballooned neurons were
observed, immunopositive for phosphorylated 4-repeat
tau (Fig. 1A), as well as widespread thread pathology in
grey and white matter (Fig. 1B), and coiled bodies in
temporal lobes (Fig. 1C). Their morphology and distribu-
tion appeared typical for sporadic frontotemporal lobar
degeneration with Corticobasal degeneration (CBD)
pathology,12,13 in keeping with MAPT mutation.14
Paternal grandmother
The patient’s paternal grandmother developed a change
in personality and behavior, with disinhibition, hoarding,
and theft. Her death aged 51 was attributed to “cerebral
atrophy”, without neuropsychological or post-mortem
examination.
Positron emission tomography using [18F]
AV-1451
PET scanning used [18F]AV-1451 and dynamic scanning
over 90 min with a GE Advance scanner. A 68Ge/68Ga
transmission scan enabled attenuation correction. Binding
potentials, relative to a nondisplaceable compartment
(BPND), were determined from kinetic analysis with a
simplified reference tissue model, using superior cerebellar
grey matter as the reference region. In older subjects with
variable perfusion, kinetic modeling overcomes the poten-
tial problem with standardized uptake value ratios arising
from a failure to reach steady state. Brain parcellation
used the Hammers brain atlas,15 expanded to include sub-
cortical structures.16
Data modeling and statistical method
Two questions were posed. Firstly, were there areas of the
brain with higher BPND in the proband than 12 healthy
adults (55–80, mean age 66, 50% male)? For each region,
a robust t-score was calculated for the patient compared
to the control group, adjusting for the relatively small size
of the sample.17 This converges with a similar Bayesian
approach.18
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Secondly, irrespective of the absolute level of ligand
binding, did the distribution of binding across brain
regions differ between the proband and healthy adults?
An hierarchical cluster analysis approach was used to
answer this question. The parcellated [18F]AV-1451 BPND
data were converted into individual linear vectors by
region of interest. These vectors were nonparametrically
correlated (Spearman’s rho), giving a correlation matrix
(Fig. 2C), and converted into a dissimilarity matrix (1
correlation, Fig. 2C). Dissimilarity fed into hierarchical
cluster analysis with thresholding for two groups using a
complete (‘farthest neighbour’) method19; the most strin-
gent linkage method for a single case (Fig. 2D).
Results
Figure 1 contains raw maps of BPND for all individuals.
Figures 2A and B illustrate the areas with significantly ele-
vated t-scores in the proband. Bonferroni correction for
83 regions-of-interest comparisons confirmed significant
differences in inferior temporal lobe, and inferior and
medial temporal pole bilaterally, as well as right superior
temporal pole (Table 1). As an indication of the sensitiv-
ity of the ligand in these regions, Table 1 also includes a
column of the maximum BPND in each region for any of
the controls, as well as the mean and standard deviation
across all controls. For the left inferior temporal lobe, the
region with the highest t-score, the control mean BPND
was 0.0086 (standard deviation 0.0346), the maximum
BPND observed in any of the controls was 0.0572, and the
MAPT patient’s BPND was 0.2928. The MAPT patient’s
BPND in this region was therefore 8.2 SD above the mean,
and 5.8 times more unusual than any of the controls.
Hierarchical cluster analysis of the distribution
(Fig. 2D) distinguished two groups. One (red in Fig. 2D)
contained 11 of the 12 healthy elderly individuals,
whereas the other (cyan in Fig. 2D) contained the patient
and 1 of the healthy individuals. Cluster analysis, blinded
by nonparametric methods to the degree of ligand bind-
ing, therefore, provided statistically significant classifica-
tion (binomial P = 0.003). The control classified together
with the patient under the farthest neighbor method was
80 years old. She did not display any cognitive abnormal-
ities (ACE-R 98/100, MMSE 30/30), but parametric t-test
comparison of this individual to the other controls
revealed higher BPND in right hippocampus (t10 = 5.14;
P < 0.05 Bonferroni corrected) and parahippocampal
gyrus (t10 = 4.53; P < 0.05 corrected), but unlike the pro-
band, the control’s BPND was not elevated in inferior
temporal lobes. Therefore, although the overall pattern of
regional binding in this control was less dissimilar from
the MAPT patient than it was from the most dissimilar of
all of the other controls, there was a clear dissociation
from the MAPT case. It is possible that [18F]AV-1451
detected asymptomatic Alzheimer’s disease pathology in
this healthy control, as expected in a proportion of older
adults. Validation linkage analysis with the ‘nearest
Figure 1. Upper panel: Representative neuropathological features of
the proband’s father’s neuropathology in the superior frontal cortex
showing a ballooned neuron (A), white matter threads (B), and a
coiled body (C) immunostained with phosphorylated tau. Scale bar
represents 20 lm in (A), 100 lm in (B), and 10 lm in (C). Second
panel: [18F]AV-1451 BPND (left) and T1-weighted MRI scan (right) for
the proband. Lower panel: [18F]AV-1451 BPND for each individual
healthy control (HC). [18F]AV-1451 BPND slices for all individuals are in
the same position in native space.
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Figure 2. Panel A: A volumetric rendering of the MNI152 template MRI brain scan, overlaid with the t-scores for ligand binding in those brain
regions meeting a one-tailed statistical threshold of P < 0.05, before (left) and after (right) correction for multiple comparisons. Panel B: coronal
and axial sections through the template brain, overlaid with the same ligand binding t-scores. Panel C left: Spearman correlation matrix between
all individuals. The first row and column, separated by black lines from the other rows and columns, represents the patient. The other 12 columns
represent controls. Panel C right: The same data expressed as dissimilarities (1 correlation). Panel D: the dendrogram produced by hierarchical
cluster analysis. The two resultant clusters are colored in red and cyan. Controls are numbered according to their order in the upper panel
correlation and dissimilarity matrices.
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neighbour’ method confirmed the patient distribution to
be unique.
Together, these results indicate that it is not simply the
case that the proband had globally elevated [18F]AV-1451
BPND, but that the BPND distribution was also signifi-
cantly different reflecting frontotemporal lobar degenera-
tion. The patient had particularly abnormal BPND in
anterior temporal lobes and ventral anterior cingulate
cortex; areas that are particularly prone to tau accumula-
tion in frontotemporal dementia,20 and that were neu-
ropathologically most abnormal in her father.
Discussion
The main finding is of a dissociated increase in [18F]AV-
1451 binding potential in the anterior temporal lobes and
ventral anterior cingulate cortex in a patient with MAPT
mutation, recapitulating the distribution of neuropathol-
ogy in her father. The mutation in this family leads to
C>T change in the MAPT pre-mRNA at position 16 of
the splice donor site of intron 10. This results in the
increased incorporation of exon 10 into MAPT mRNA,
creating an accumulation of the 4-repeat tau isoform neu-
ropathologically resembling CBD.21
The validation of tau tracers would have major implica-
tions for diagnosis and clinical trials in disorders associated
with frontotemporal lobar degeneration. PET studies in
cases with MAPT mutations provide an important facet of
such validation, especially in combination with a strong,
clear history, and the availability of neuropathological con-
firmation.
The primary limitation of this study is that it does not
address the specificity of binding of [18F]AV-1451. This
will require further work in other neurodegenerative dis-
orders, notably those with TDP-43 deposition.
In conclusion, the intensity and distribution of binding
of the tau ligand [18F]AV-1451 in a patient with a MAPT
10 + 16C>T mutation supports the use of this ligand in
Table 1. Corrected t-scores from brain regions with statistically significant ligand binding potential (BPND) at P < 0.05 uncorrected.
Hammers Atlas
Brain Region Simplified Name
Hammers
Region
Number
MAPT
BPND
Control
BPND max
Control
BPND mean
Control
BPND SD
Corrected
t-score
‘G_tem_midin_l’ Left Inferior Temporal 14 0.2928 0.0572 0.0086 0.0346 7.90
‘Ant_TL_inf_lat_r’ Right Inferior Temporal Pole 7 0.5925 0.1342 0.0557 0.0738 6.99
‘G_tem_midin_r’ Right Inferior Temporal 13 0.3367 0.0793 0.0140 0.0447 6.93
‘Ant_TL_med_l’ Left Medial Temporal Pole 6 0.3118 0.0690 0.0094 0.0441 6.59
‘Ant_TL_inf_lat_l’ Left Inferior Temporal Pole 8 0.3950 0.1245 0.0478 0.0540 6.18
‘Ant_TL_med_r’ Right Medial Temporal Pole 5 0.2774 0.0860 0.0071 0.0485 5.36
‘G_sup_temp_ant_r’ Right Superior Temporal Pole 83 0.4292 0.2080 0.1191 0.0705 4.23
‘G_sup_temp_ant_l’ Left Superior Temporal Pole 82 0.3792 0.1995 0.0809 0.0721 3.97
‘Putamen_r’ Right Putamen 39 0.4353 0.3568 0.2369 0.0552 3.45
‘G_sup_temp_cent_r’ Right Superior Temporal 11 0.2122 0.1181 0.0377 0.0495 3.39
‘Subcall_area_r’ Right Ventral Anterior
Cingulate Cortex
79 0.3919 0.2645 0.1296 0.0751 3.35
‘Pallidum_r’ Right Pallidum 43 0.5226 0.3514 0.2128 0.0995 2.99
‘G_occtem_la_r’ Right Perirhinal Cortex 15 0.2112 0.1277 0.0059 0.0660 2.99
‘Pallidum_l’ Left Pallidum 42 0.4468 0.3797 0.1909 0.0864 2.84
‘Cerebellum_wm_r’ Right Cerebellar Grey Matter 90 0.0009 0.0280 0.0614 0.0219 2.65
‘G_occtem_la_l’ Left Perirhinal Cortex 16 0.1677 0.1223 0.0233 0.0531 2.61
‘Amygdala_r’ Right Amygdala 3 0.2248 0.1413 0.0535 0.0636 2.59
‘NuclAccumb_r’ Right Caudate 37 0.4768 0.4355 0.1970 0.1083 2.48
‘PosteriorTL_r’ Right Posterior Temporal 31 0.0934 0.0625 0.0019 0.0386 2.37
‘G_sup_temp_cent_l’ Left Superior Temporal 12 0.1400 0.1135 0.0291 0.0452 2.36
‘Putamen_l’ Left Putamen 38 0.3947 0.3750 0.2463 0.0617 2.31
‘Insula_r’ Right Insula 21 0.1693 0.1198 0.0531 0.0493 2.26
‘S_nigra_r’ Right Midbrain 75 0.4506 0.3863 0.2332 0.0958 2.18
‘CaudateNucl_r’ Right Caudate 35 0.3383 0.3522 0.1738 0.0787 2.01
‘Subgen_antCing_l’ Left Ventral Anterior Cingulate Cortex 76 0.1090 0.0752 0.0107 0.0578 1.99
‘Amygdala_l’ Left Amygdala 4 0.1800 0.1838 0.0514 0.0670 1.84
‘Cerebellum_dentate_r’ Right Cerebellar Dentate 239 0.0850 0.0697 0.0208 0.0342 1.80
‘FL_strai_G_r’ Right Medial Orbitofrontal Cortex 53 0.2492 0.2452 0.1297 0.0646 1.78
Regions surviving Bonferroni correction for 83 comparisons (P < 0.0006) are in bold. For each region, the BPND for the MAPT patient is given,
along with the maximum BPND observed in any of the controls and the mean and standard deviation of BPND across all controls.
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clinical studies of dementia, including frontotemporal
lobar degeneration and CBS.
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Appendix
Macroscopic Observations
Following removal at autopsy, the brain was fixed in 15%
neutral buffered formalin, and weighed 1420 g. The cerebel-
lum and brainstem were separated from the cerebrum. Exam-
ination of the external surfaces found moderate cerebral
atrophy, which was most prominent in the frontal and tem-
poral lobes. The left temporal lobe was more severely affected
than the right temporal lobe. The atrophy extended to involve
the precentral gyrus and the superior parietal gyrus. The cere-
bral hemispheres were sectioned in the coronal plane. The
cerebral atrophy observed externally was confirmed and there
was enlargement of the lateral ventricles. The basal ganglia
and thalami were unremarkable, although the subthalamic
nucleus was slightly reduced in size. Horizontal sections of the
brainstem revealed pallor of the substantia nigra and locus
coeruleus. Apart from a small single infarct in the cerebellar
cortex, the cerebellum was unremarkable.
Tissue Preparation and
Immunohistochemistry
Standard tissue blocks from the superior frontal, precen-
tral, inferior temporal and anterior cingulate cortices, the
hippocampus at the level of the lateral geniculate nucleus,
the basal ganglia at the level of the head of the caudate
nucleus, the midbrain at the level of the red nucleus, the
pons at the level of the locus coeruleus, subthalamic
nucleus, the medulla at the level of the hypoglossal nucleus,
and the cerebellar dentate gyrus were embedded in paraffin
wax and cut on a rotary microtome. Ten lm sections were
stained using hematoxylin and eosin and modified
Bielschowsky silver. Immunoperoxidase staining using
phosphorylated tau (clone AT8; mouse; 1:1000; Cat. No.
MN1012; Thermo Scientific Australia, Scoresby, Victoria)
was performed using a Discovery DX autostainer (Ventana
Medical Systems, Tuscon, AZ, USA). 3-repeat tau (mouse;
1:50; Cat. No. 05-803; Abcam; Melbourne, Victoria), 4-
repeat tau (mouse; 1:50; Cat. No. 05-804; Abcam), p62
(rabbit; 1:250; Cat. No. 610833; BD Biosciences; North
Ryde, NSW), and alpha-synuclein (mouse; 1:500; Cat. No.
610787; BD Biosciences; North Ryde, NSW) were per-
formed manually. For antigen retrieval, 3-repeat tau and
p62 required heating in the pressure cooker at 110°C for
half an hour in TE buffer (pH 9.0), 4-repeat tau required
pretreatment with formic acid for 15 min followed by
heating in the pressure cooker at 110°C for half an hour in
TE buffer, and alpha-synuclein required pretreatment with
citric acid buffer (pH 6.0) for 18 min in the microwave.
Following blocking of endogenous peroxidase activity in
100% methanol with 3% hydrogen peroxide for 10 min,
sections were blocked in 10% normal horse serum (NHS)
in TBS buffer (pH 7.4). Primary antibodies diluted in TBS
with 1% NHS were incubated at 37°C for 1 h, followed by
incubation in EnVision Dual Link Polymer (Cat. No.
K4061; DAKO; North Sydney, New South Wales). Dark
brown staining was visualized by adding hydrogen peroxi-
dase to a 3030-diaminobenzidine solution. All sections were
counterstained with hematoxylin.
Microscopic Observations
Histopathology
Sections of the cerebral cortex showed mild neuronal loss
and gliosis in the superior frontal and inferior temporal
cortices with the normal laminar distribution of neurons
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preserved. Ballooned neurons were observed in cortical
sections stained with hematoxylin and eosin. Both the
hippocampal CA1 region and entorhinal cortex showed
mild neuronal loss and sparse neurofibrillary tangles.
Neuritic plaques were not observed. Consistent with the
macroscopic examination, there was mild neuronal loss of
pigmented neurons in the substantia nigra and depigmen-
tation in both the substantia nigra and locus coeruleus.
The basal ganglia and cerebellum had minimal neuronal
loss.
Tau immunohistochemistry
Phosphorylated tau-immunopositive ballooned neurons
(Fig 1A), astrocytic plaques, widespread grey and white
matter thread pathology (Fig 1B), and coiled bodies
(Fig 1C) were observed in the superior frontal and infe-
rior temporal cortices. The morphology and distribution
of these inclusions appeared similar to sporadic fron-
totemporal lobar degeneration cases with CBD pathologi-
cal subtype.12,13 Immunostaining with 4-repeat tau and
p62 labeled a similar number of ballooned neurons, astro-
cytic plaques, and coiled bodies. Both 4-repeat tau and
p62 only labeled a small proportion of phosphorylated
tau-immunopositive threads in both grey and white mat-
ter. 3-repeat tau immunoreactivity was not observed.
Phosphorylated tau-immunopositive Pick bodies and
tufted astrocytes were not observed. Immunostaining with
alpha-synuclein was not observed in the cortex, hip-
pocampus, or brainstem. The severity of neuropathological
features immunostained with phosphorylated tau was simi-
lar in both the superior frontal and inferior temporal cortices
with a mild number of ballooned neurons and astrocytic pla-
ques, and moderate-to-severe coiled bodies and thread
pathology in grey and white matter of both regions.
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